FATE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.8 USD | -1.81% |
|
-20.67% | +1.60% |
| Sales 2024 * | 4.73M 379M | Sales 2025 * | 4.85M 388M | Capitalization | 433M 34.62B |
|---|---|---|---|---|---|
| Net income 2024 * | -195M -15.61B | Net income 2025 * | -211M -16.89B | EV / Sales 2024 * | 48.8 x |
| Net cash position 2024 * | 202M 16.15B | Net cash position 2025 * | 124M 9.93B | EV / Sales 2025 * | 63.6 x |
| P/E ratio 2024 * |
-2.04
x | P/E ratio 2025 * |
-2.24
x | Employees | 181 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.53% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fate Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -1.81% | ||
| 1 week | -20.67% | ||
| Current month | -48.23% | ||
| 1 month | -44.61% | ||
| 3 months | -16.67% | ||
| 6 months | +117.14% | ||
| Current year | +1.60% |
1 week
3.74
5.02
1 month
3.747.65
Current year
3.468.83
1 year
1.638.83
3 years
1.6397.43
5 years
1.63121.16
10 years
1.46121.16
| Managers | Title | Age | Since |
|---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 26/04/07 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 16/08/20 |
| Chairman | 75 | 31/10/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 69 | 16/03/14 |
Robert Hershberg
BRD | Director/Board Member | 61 | 30/04/20 |
Tim Coughlin
BRD | Director/Board Member | 57 | 31/07/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.95% | 1 M€ | 0.00% | - | |
| 2.10% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.8 | -1.81% | 2,732,203 |
| 25/04/24 | 3.87 | -10.00% | 3,601,787 |
| 24/04/24 | 4.3 | -5.29% | 2,273,158 |
| 23/04/24 | 4.54 | -5.02% | 4,022,308 |
| 22/04/24 | 4.78 | -0.21% | 1,434,149 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Calendar
30/04/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
3.8
USD
Average target price
7.8
USD
Spread / Average Target
+105.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.60% | 433M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- FATE Stock
